Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2026-03-06 00:00:00 ET · period of report 2026-03-05 · accession 0001193125-26-096512 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-03-06 | 2026-03-05 | DYN | Cox John | CEO, Pres, Dir | S - Sale | $14.90 | -2,732 | 374.1K | -0.7% | -$40.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-05 | S | D | 2,732 | $14.90 | 374,145 | D | — | — | (F2) Includes 279,895 unvested RSUs. |